Board Changes at Novogen Limited Announced
March 23, 2009 10:46 ET
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 23, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William
D. Rueckert to its Board of...
Novogen's NV-128, a Novel mTOR Inhibitor, Shows Potential Activity Against Cancer Stem Cells
December 01, 2008 08:10 ET
|
NOVOGEN LIMITED
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 1, 2008) - Pharmaceutical company
Novogen Limited (NASDAQ: NVGN) (ASX: NRT) today announced that work
performed in collaboration with a...
Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination
October 30, 2008 19:19 ET
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - October 30, 2008) - Pre-clinical studies
presented at the 9th International Conference on Membrane Redox Systems in
Wellington New Zealand this...
Novogen Signs Spanish Patent License With Laboratorios Casen-Fleet
June 23, 2008 08:00 ET
|
Novogen, Limited
STAMFORD, CT and SYDNEY, AUSTRALIA--(Marketwire - June 23, 2008) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN), the registered owner of the European Patent "Use of
isoflavone phyto-oestrogen extracts...
Novogen's NV-128 Is a Unique Inhibitor of mTOR Dephosphorylation Leading to Caspase Independent Death in Chemoresistant Cancer Cells
April 15, 2008 17:25 ET
|
Novogen, Limited
SAN DIEGO, CA--(Marketwire - April 15, 2008) - Pre-clinical studies reviewed during an oral
presentation here today at the annual meeting of the American Association
for Cancer Research demonstrate...
Novogen Cardiovascular Drug Enters Phase I Clinical Trial
April 02, 2008 08:00 ET
|
Novogen, Limited
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - April 2, 2008) - Novogen today
announced the commencement of a Phase I human clinical trial of the novel
cardiovascular drug, NV-27. This drug is...
Glycotex, Inc. Obtains Active IND From US Food and Drug Administration for GLYC-101 Wound Healing Compound
January 07, 2008 18:58 ET
|
Glycotex, Inc., Novogen Limited
ROCKVILLE, MD--(Marketwire - January 7, 2008) - Glycotex, Inc. announced today that it had
obtained an active Investigational New Drug Application (IND) from the US
Food and Drug Administration (FDA)...
Novogen's Investigational Drug for Inflammatory Bowel Disease Has Positive Results Following Phase Ib Trial
December 04, 2007 08:01 ET
|
Novogen, Limited
STAMFORD, CT and SYDNEY, AUSTRALIA--(Marketwire - December 4, 2007) - A recently completed
Phase Ib clinical trial of a new drug to treat inflammatory bowel disease
(IBD) indicates that treatment may...
Research Indicates Synthetic Compound NV-52 May Be Useful in Treatment of Inflammatory Bowel Disease
November 13, 2007 08:04 ET
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - November 13, 2007) - An article published
in a recent edition of the peer review journal Expert Opinion, Vol. 16, No.
8, reveals the compound...
Novogen Announces Collaboration Agreement to Bring Cosmetic Products to Market
October 25, 2007 20:00 ET
|
Novogen
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - October 25, 2007) - Novogen Limited
(NASDAQ: NVGN) announced today a collaboration agreement to develop new
cosmetic applications. The finished...